PMID- 21552458
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1874-3250 (Electronic)
IS  - 1874-3250 (Linking)
VI  - 5
DP  - 2011 Mar 16
TI  - Effect of a direct thrombin inhibitor compared with dalteparin and unfractionated 
      heparin on human osteoblasts.
PG  - 52-8
LID - 10.2174/1874325001105010052 [doi]
AB  - PURPOSE: Osteoporosis is a relevant problem after long term administration of 
      unfractionated heparin (UFH) and low molecular weight heparin. Melagatran is a 
      representative of a new group of direct thrombin inhibitors with comparable data 
      in the prevention of thromboembolic events after orthopaedic surgery. The aim of 
      our in vitro study was to investigate the effect of a direct thrombin inhibitor 
      compared with dalteparin and UFH on human osteoblasts. MATERIALS AND METHODS: 
      Melagatran, dalteparin and UFH were added to primary osteoblast cultures in their 
      therapeutic range and two decimal powers below and above. Cell number, protein 
      synthesis, mitochondrial and alkaline phosphatase activity and collagen type I 
      synthesis were evaluated. RESULTS: Melagatran showed the least influence on 
      protein synthesis and cell proliferation with a reduction of cell number to 83.5 
      +/- 9% (p = 0.027) of the control group only in the highest investigated 
      concentration after 15 days of incubation. Mitochondrial and alkaline phosphatase 
      activity and collagen type I synthesis in osteoblasts incubated with melagatran 
      and dalteparin showed similar patterns. UFH showed the most pronounced influence 
      on cellular metabolism. CONCLUSIONS: Melagatran showed less inhibitory in vitro 
      effects on human osteoblasts than dalteparin or UFH. The presented study gives 
      first hints that direct thrombin inhibitors may help prevent heparin-induced 
      negative effects on bone metabolism.
FAU - Winkler, Tobias
AU  - Winkler T
AD  - Center of Musculoskeletal Surgery, Berlin Brandenburg Center for Regenerative 
      Medicine, Charite - Universitaetsmedizin Berlin, Germany.
FAU - Perka, Carsten
AU  - Perka C
FAU - Matziolis, Dorte
AU  - Matziolis D
FAU - Matziolis, Georg
AU  - Matziolis G
LA  - eng
PT  - Journal Article
DEP - 20110316
PL  - United Arab Emirates
TA  - Open Orthop J
JT  - The open orthopaedics journal
JID - 101480491
PMC - PMC3087215
OTO - NOTNLM
OT  - Direct thrombin inhibitor
OT  - dalteparin
OT  - heparin
OT  - osteoblasts
OT  - osteoporosis.
EDAT- 2011/05/10 06:00
MHDA- 2011/05/10 06:01
PMCR- 2011/01/01
CRDT- 2011/05/10 06:00
PHST- 2010/08/08 00:00 [received]
PHST- 2011/01/11 00:00 [revised]
PHST- 2011/01/13 00:00 [accepted]
PHST- 2011/05/10 06:00 [entrez]
PHST- 2011/05/10 06:00 [pubmed]
PHST- 2011/05/10 06:01 [medline]
PHST- 2011/01/01 00:00 [pmc-release]
AID - TOORTHJ-5-52 [pii]
AID - 10.2174/1874325001105010052 [doi]
PST - epublish
SO  - Open Orthop J. 2011 Mar 16;5:52-8. doi: 10.2174/1874325001105010052.